Genome Biology (Mar 2024)

Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes

  • Adrià Aterido,
  • María López-Lasanta,
  • Francisco Blanco,
  • Antonio Juan-Mas,
  • María Luz García-Vivar,
  • Alba Erra,
  • Carolina Pérez-García,
  • Simón Ángel Sánchez-Fernández,
  • Raimon Sanmartí,
  • Antonio Fernández-Nebro,
  • Mercedes Alperi-López,
  • Jesús Tornero,
  • Ana María Ortiz,
  • Carlos Marras Fernández-Cid,
  • Núria Palau,
  • Wenjing Pan,
  • Miranda Byrne-Steele,
  • Dmytro Starenki,
  • Daniel Weber,
  • Ivan Rodriguez-Nunez,
  • Jian Han,
  • Richard M. Myers,
  • Sara Marsal,
  • Antonio Julià

DOI
https://doi.org/10.1186/s13059-024-03210-0
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 36

Abstract

Read online

Abstract Background In rheumatoid arthritis (RA), the activation of T and B cell clones specific for self-antigens leads to the chronic inflammation of the synovium. Here, we perform an in-depth quantitative analysis of the seven chains that comprise the adaptive immune receptor repertoire (AIRR) in RA. Results In comparison to controls, we show that RA patients have multiple and strong differences in the B cell receptor repertoire including reduced diversity as well as altered isotype, chain, and segment frequencies. We demonstrate that therapeutic tumor necrosis factor inhibition partially restores this alteration but find a profound difference in the underlying biochemical reactivities between responders and non-responders. Combining the AIRR with HLA typing, we identify the specific T cell receptor repertoire associated with disease risk variants. Integrating these features, we further develop a molecular classifier that shows the utility of the AIRR as a diagnostic tool. Conclusions Simultaneous sequencing of the seven chains of the human AIRR reveals novel features associated with the disease and clinically relevant phenotypes, including response to therapy. These findings show the unique potential of AIRR to address precision medicine in immune-related diseases.